In a recent post by Oncology Nursing News, Dr. Gina D’Amato, associate professor and assistant director of Clinical Research at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the evolution of treatment in sarcoma, the use of NGS, and predictive and prognostic biomarkers under investigation in the space.
Exciting Advancements in Sarcoma Treatment
Though the use of next-generation sequencing (NGS) may not have immediate clinical implications for patients with sarcoma, it can provide valuable information for data collection and position patients for ongoing clinical trials that have the potential to push the needle forward, explained Gina Z. D’Amato, MD.
“There are over 170 different types of sarcomas. In the past, we’ve lumped these sarcomas together, so treatment outcomes have not been optimal,” said D’Amato. “As we’re learning more about the different subtypes and the different molecular processes that are involved in the oncogenesis [of the disease, we’re better able to] develop different targeted therapies.” Read more…